



## ROLE OF $\gamma$ -GLUTAMYLTRANSFERASE IN PUTRESCINE UPTAKE BY RAT TYPE II PNEUMOCYTES

ROB J. VAN KLAVEREN, PETER H. M. HOET, MAURITS DEMEDTS and BENOIT NEMERY\*

Laboratory of Pneumology, Unit of Lung Toxicology, K.U.Leuven Herestraat 49, B-3000 Leuven, Belgium

(Received 8 February 1995; accepted 17 May 1995)

**Abstract**—Putrescine uptake in type II pneumocytes is a carrier-mediated active process. Our hypothesis was that oligoamines might be taken up into the cell at least in part by  $\gamma$ -glutamyltransferase ( $\gamma$ -GT). This was investigated in rat type II pneumocytes 24 hr after their isolation. Preexposure to 125  $\mu$ M L-buthionine-[SR]-sulfoximine (BSO) or 100  $\mu$ M diethylmaleate (DEM), both of which affect intracellular glutathione (GSH) only, were found to decrease GSH by 85% ( $p < 0.05$ ) and 62%, respectively ( $p < 0.05$ ), without change in [ $^3$ H]-putrescine uptake. Preexposure to 20  $\mu$ M N-ethylmaleimide (NEM), which affects intra- and extracellular GSH, decreased intracellular GSH by 79% ( $p = 0.015$ ) and putrescine uptake by 39% ( $p = 0.03$ ). Selective extracellular GSH depletion by 10  $\mu$ M copper-o-phenanthroline complex (CuP) led to a decrease in putrescine uptake of 41% ( $p = 0.001$ ), while intracellular GSH remained unchanged. Specific inhibition of  $\gamma$ -GT by 5–20 mM serine-borate or 5 mM acivicin gave similar degrees of putrescine uptake inhibition (39.5% and 40.5%). The kinetic properties of the putrescine uptake system in the presence of acivicin and serine-borate indicated that the  $V_{max}$  decreased by 25%, while  $K_m$  remained unchanged. In experiments with pure  $\gamma$ -GT, the oligoamines putrescine, spermidine and spermine, and cystamine proved to be acceptor substrates for  $\gamma$ -GT, all having similar efficiencies ( $V_{max}/K_m$ ); methylglyoxal-bis-(guanyl-hydrazone) and paraquat were not accepted. As extracellular GSH is required for  $\gamma$ -GT, and because its extracellular depletion inhibits putrescine uptake as much as specific inhibition of  $\gamma$ -GT, we suggest that 30–40% of the putrescine uptake in type II pneumocytes occurs by  $\gamma$ -GT and that, therefore, at least two systems are involved in the uptake of putrescine.

**Key words:** putrescine;  $\gamma$ -glutamyltransferase; paraquat; cystamine; polyamines; cell culture

The oligoamines (or polyamines) putrescine, spermidine, and spermine are organic cations that play an important role in cell growth, differentiation, and proliferation [1]. Previous studies have shown that one or more transport systems might be involved in the cellular uptake of oligoamines, and that pulmonary type II pneumocytes especially exhibit high uptake activity [2–5]. The pneumotoxic herbicide paraquat has been shown to accumulate in lung cells by a process that is apparently identical to that which accumulates putrescine [5, 6]. Although many authors have studied the characteristics of the paraquat/polyamine uptake system(s) [2–7], the transport system itself has not yet been identified in mammalian cells.

Previous investigations have indicated that –SH groups are required for oligoamine uptake [7–9]. Glutathione (GSH) is the most abundant intracellular thiol, and has many biological functions. It has been proposed by Meister and co-workers [10] that circulating GSH, produced principally by the liver, is the major source of the cysteine required for *de novo* intracellular GSH synthesis through the sequential actions of  $\gamma$ -glutamyltrans-

ferase ( $\gamma$ -GT),  $\gamma$ -glutamylcysteine synthetase, 5-oxoprolinase, and glutathione synthetase (Fig. 1).  $\gamma$ -GT, which is membrane-bound and localized on the external surface of cells, is involved in the transport of amino acids across the cell membrane into the cell [11–13]. As a first step in the  $\gamma$ -GT cycle,  $\gamma$ -GT breaks the  $\gamma$ -glutamylcysteine bond of extracellular GSH, and the  $\gamma$ -glutamyl moiety is transferred to an acceptor substrate, usually an amino acid, thus resulting in the formation of a  $\gamma$ -glutamyl-dipeptide. Subsequently, the  $\gamma$ -glutamyl-dipeptide, as well as cysteinylglycine, is taken up by the cell and catabolized to glutamate and free amino acids by the action of  $\gamma$ -glutamylcyclotransferase and cysteinylglycine dipeptidase. It has been shown that certain tumor cells express more  $\gamma$ -GT on their cell membranes compared to normal cells, and this might be correlated with an unfavourable prognosis [14, 15].

Since both the putrescine uptake system and, at least indirectly, the  $\gamma$ -glutamyl cycle are involved in growth and differentiation of cells, our hypothesis is that one of the routes by which oligoamines are taken up into the cell is via the  $\gamma$ -glutamyl cycle. Binding of the amino group to the carboxamide group of the  $\gamma$ -glutamyl residue might be possible by analogy to the transglutaminase-catalysed binding of diamines and polyamines to peptide chains [16, 17]. Indeed,  $\gamma$ -GT not only binds to amino acids, dipeptides, and tripeptides, but studies on  $\gamma$ -GT in plants have shown that amines may also function as acceptor substrates for this “high capacity-low specificity” enzyme [18].

The aim of our study was to verify (a) whether  $\gamma$ -GT is involved in the uptake of putrescine; and (b) whether manipulation of GSH level will modify the uptake of putrescine.

\* Corresponding author. Tel. (32)16 347121; Fax (32)16 347124.

† Abbreviations: BSO, L-buthionine-[SR]-sulfoximine; DEM, diethylmaleate; NEM, N-ethylmaleimide; CuP, copper-o-phenanthroline; MGBG, methyl-glyoxal-bis-(guanyl-hydrazone); BSA, bovine serum albumin;  $\gamma$ -GT,  $\gamma$ -glutamyltransferase; GSH, glutathione; DTNB, 5,5-dithio-(2-nitro)-benzoic acid; FCS, fetal calf serum; SSA, 5-sulfosalicylic acid; PBS<sup>+</sup> and PBS<sup>−</sup>, phosphate buffered saline with or without calcium and magnesium, respectively;  $V_{max}$ , the maximal rate of uptake;  $K_m$ , the medium concentration at which the rate of uptake is half  $V_{max}$ ; dpm, disintegrations per minute; cpm, counts per minute.




Fig. 1. Schematic representation of the  $\gamma$ -glutamyl cycle. Amino acids are translocated by  $\gamma$ -GT across the cell membrane by binding to the  $\gamma$ -glutamyl moiety of GSH, and are released by the action of  $\gamma$ -glutamyl cyclotransferase within the cell. The long arrowheads indicate sites of inhibition (after Meister *et al.* [29]).  $\gamma$ -GT =  $\gamma$ -Glutamyltransferase, DEM = diethylmaleate, BSO = L-buthionine-[SR]-sulfoximine.

## MATERIALS AND METHODS

### Animals and materials

Male Wistar rats (140–170 g) were obtained from an in-house strain. [1,4(n)- $^3\text{H}$ ]putrescine dihydrochloride [14.6 Ci/mmol (1  $\mu\text{Ci}/\mu\text{l}$ )] was purchased from Amersham International Ltd. (Brussels, Belgium), and Emulsifier Safe scintillant and plastic scintillation vials (5 ml) were purchased from Packard N.V. (Zellik, Belgium). Paraquat dichloride (99% pure, Plant Protection Division, ICI plc, now Zeneca) was a gift from Dr L. L. Smith (Central Toxicology Laboratory, ICI plc, now Zeneca). Putrescine dihydrochloride, L-serine, sodium tetraborate, acivicin (L-( $\alpha$ S,5S)- $\alpha$ -amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid), MGBG $^+$ , cystamine, L-cysteine, glutathione, NEM, DEM, BSO, cupric sulfate, o-phenanthroline, L- $\gamma$ -glutamyl-p-nitroanilide, glycylglycine, spermidine, spermine, proline, trypsin type I (EC 3.4.214), trizma base (Tris), bovine serum albumine (BSA), DNase I, glutathione reductase type IV (EC 1.6.4.2, 100 U/mL),  $\gamma$ -glutamyl-transferase type I (EC 2.3.2.2., 6 U/mg),  $\beta$ -Nicotinamide-adenine-dinucleotide-phosphate, reduced form ( $\beta$ -NADPH), Percoll, and 5,5-dithio-(2-nitro)-benzoic acid (DTNB) were all purchased from Sigma Germany (Filter Service NV/SA, Eupen, Belgium). Waymouth's 752/1 medium, Dulbecco's Modified Eagle 11880 Medium without phenol red and GSH (DMEM), fungizone (amphotericin 250  $\mu\text{g}/\text{mL}$ ), L-glutamine (200 mM), penicillin-streptomycin solution (10,000 U–10,000  $\mu\text{g}/\text{mL}$ , respectively), Hepes, and fetal calf serum (FCS) were purchased from Gibco (Merelbeke, Belgium), and 5-sulfosalicylic acid (SSA) was purchased from Merck, Germany. Protein assay dye solution was purchased from Bio-Rad (Brussels, Belgium). All other chemicals were purchased from U.C.B. Belgium (Vel NV/SA, Leuven, Belgium). Ninety-six-well cell-culture plates coated with extracellular matrix (ECM) were purchased from Biological Industries, Glasgow, U.K.

### Isolation of rat type II pneumocytes

The isolation procedure was based on the methods of Richards *et al.* [19] and Hoet *et al.* [3]. Briefly, rats were deeply anaesthetized by an intraperitoneal injection of 60 mg pentobarbital/kg body weight (Nembutal, 60 mg/ml). After perfusion of the lungs with 0.9% NaCl, the lungs and trachea were removed from the thoracic cavity, and 6–8 mL 0.9% NaCl were instilled and withdrawn five times via a tracheal cannula. After the last lavage, the lungs were filled with a trypsin solution (500 mg trypsin in 200 mL PBS $^+$  containing 130 mM NaCl, 5.4 mM KCl, 11 mM glucose, 10.6 mM Hepes, and 2.6 mM  $\text{Na}_2\text{HPO}_4$  adjusted to pH 7.4, plus 1.9 mM  $\text{CaCl}_2$  and 1.29 mM  $\text{MgSO}_4$ ). After a first incubation with trypsin for 5 minutes, fresh trypsin solution was instilled for 30 min at 37°C. After this digestion period, the trachea and main bronchi were removed from the lungs; the lungs were chopped for 5 minutes with scissors; 5 ml FCS and 15 ml DNase solution (250  $\mu\text{g}/\text{mL}$  PBS $^-$ ) were added; and the tube was shaken by hand for 5 minutes. The digest was filtered through a cotton gauze and two Nylon filters (mesh 80 and 25  $\mu\text{m}$ ; Heleine Cavenaile PVBA/SPRL, Brussels, Belgium), and centrifuged at 250 g for 20 minutes (4°C) on a discontinuous Percoll gradient (density 1.089 g/mL and 1.040 g/mL). The creamy layer above the heavy gradient was collected, rinsed in PBS $^-$ , suspended in Waymouth's medium supplemented with DNase 50  $\mu\text{g}/\text{mL}$ , 2% FCS, 2% fungizone, and 2% penicillin-streptomycin solution, and incubated for 1 hr in a Petri dish placed in a CO $_2$  incubator (10% CO $_2$ , 37°C) in order to let the macrophages attach. The unattached cells were then spun down (250 g, 10 min) and resuspended in the final Waymouth's medium containing 10% (v/v) FCS, 1% fungizone, 1% penicillin-streptomycin solution, and 1% L-glutamine. The cells were counted in a Buerker chamber and plated on 96-well plates (100,000 type II cells/200  $\mu\text{l}/\text{well}$ ). The cells were used 24 hr after plating, and were rinsed with PBS $^+$ .

to remove non-adherent cells. This procedure yielded more than 95% viable type II pneumocytes, as determined by Trypan Blue exclusion.

#### GSH determination

Total GSH (GSH + GSSG) was determined using GSH-reductase according to the procedure of Anderson [20], by which GSH can be detected in the picomolar range. 700  $\mu$ L buffer (143 mM sodium phosphate, 6.3 mM  $\text{Na}_4\text{-EDTA}$ , and 0.35 mM  $\beta\text{-NADPH}$ , pH 7.5), 100  $\mu$ L 6 mM DTNB, 150  $\mu$ L water, and 50  $\mu$ L sample containing 2.5% SSA (w/v) were transferred to a cuvette and heated to 37°C. Then 10  $\mu$ L GSH-reductase (100 U/mL) were added, with mixing, to initiate the assay. The change in absorbance was measured at 412 nm, using a Beckman DU65 spectrophotometer. For each run, a standard curve was prepared. The samples were obtained by treating the cells with 50  $\mu$ L 2.5% SSA (w/v) per well for 30 min. For each data point, the mean GSH concentration of two wells was taken. The protein concentration for each well ( $\pm 50$   $\mu$ g) was determined afterwards by dissolving the precipitated proteins in 200  $\mu$ L NaOH and, after neutralization with 1 M HCl, the concentration was measured using the method of Bradford [21]. The GSH concentration was expressed as nmol/mg protein. GSSG was not determined because it was not playing a role in this study. Preliminary experiments (data not shown) indicated that prior detachment of the cells from the culture plate by trypsin, followed by precipitation in SSA, centrifugation, and GSH determination in the supernatant gave similar results, but because this method was cumbersome, it was abandoned. For the measurement of GSH in the extracellular fluid, the Waymouth's medium was replaced by DMEM (i.e. GSH free medium) after the cells had been rinsed with PBS<sup>+</sup>.

#### Accumulation of putrescine in cultured type II pneumocytes

Putrescine uptake experiments were performed according to Hoet *et al.* [3]. Briefly, after removal of the Waymouth's medium, the cells were incubated at 37°C or 4°C for 1 hr in 200  $\mu$ L PBS<sup>+</sup> containing 10  $\mu$ M putrescine and 0.1  $\mu$ Ci [<sup>3</sup>H]-putrescine. After incubation, the wells were rinsed three times with 200  $\mu$ L cold PBS<sup>+</sup> containing 10  $\mu$ M unlabelled putrescine. Next, the cells were dissolved in 200  $\mu$ L NaOH (0.1 M) for at least 3 hr and 4.5 mL Emulsifier scintillant were added, and radioactivity was measured by liquid scintillation spectrophotometry, using a Beckman LS5000ce counter, fitted with appropriate quench correction curves to convert cpm to dpm. The accumulation of putrescine, expressed as pmol/mg protein/hr, was obtained from the tissue-associated radioactivity, the specific activity of [<sup>3</sup>H]-putrescine, and the protein concentration of identically treated cells, measured as above after neutralisation with 0.1 M HCl prior to protein measurement.

#### Intra- and extracellular GSH and putrescine uptake

Prior to putrescine uptake studies, cells were preincubated at 37°C with four different GSH-modifying compounds [12]: 125  $\mu$ M BSO in Waymouth's medium for 2 hr; 100  $\mu$ M DEM (prepared from a 50 mM DEM stock solution made up of 86  $\mu$ L DEM dissolved in 0.3 mL ethanol and 9.7 mL PBS<sup>+</sup>) in Waymouth's medium for 2 hr; and 20  $\mu$ M NEM in PBS<sup>+</sup> for 5 min. Concomitant with the putrescine uptake, the cells were also exposed to

a 10  $\mu$ M copper-o-phenanthroline (CuP) complex, with a 1:2 molar ratio of Cu:P (prepared from a 10 mM CuP stock solution, made up by mixing 24.9 mg cupric sulphate dissolved in 9.7 mL water with 39.6 mg phenanthroline dissolved in 0.3 mL ethanol), in PBS<sup>+</sup> [22, 23]. Controls were also exposed to ethanol, as appropriate.

#### Putrescine uptake inhibition

Concomitant with the putrescine uptake, cells were exposed to possible modulators of  $\gamma$ -GT: 5, 50, 500, or 5000  $\mu$ M acivicin; 5 mM L-serine alone, 20 mM sodium tetraborate alone, 2.5 mM L-serine plus 10.0 mM sodium tetraborate, or 5.0 mM L-serine plus 20.0 mM sodium tetraborate, all in PBS<sup>+</sup>, adjusted for pH and osmolarity; 10 or 20  $\mu$ M GSH; 10 or 20  $\mu$ M L-cysteine; 20 or 40  $\mu$ M MGBG; 12.5, 25, 50 or 100  $\mu$ M cystamine; 100, 200, 400, 1250, or 2500  $\mu$ M paraquat.

#### The $\gamma$ -GT assay

$\gamma$ -GT was assayed as described by Meister *et al.* [10]. Briefly, 0.2 mL L- $\gamma$ -glutamyl-p-nitroanilide (final concentration 1 mM), 0.59 mL 0.1 M Tris-HCl buffer (pH 8.0), and 0.2 mL of the acceptor substrate were brought to 37°C in a cuvette; 10  $\mu$ L of  $\gamma$ -glutamyltransferase type I (60 units/mL) were added, the cuvette shaken, and the change in absorbance recorded at 410 nm for 2 min using a Beckman DU65 spectrophotometer. Enzyme activity was expressed as micromoles p-nitroaniline formed per minute (Units), using a molar extinction coefficient of 568  $\text{mM}^{-1}\text{cm}^{-1}$  for the conversion from  $\Delta A$  to Units/L [24]. The relatively high donor substrate concentration was used to minimize hydrolysis [9]. The assay was performed with 0–160 mM of different potential acceptors: glycylglycine, L-cysteine, putrescine, spermidine, spermine, MGBG, cystamine, paraquat, and cystamine. After subtracting the change in absorbance due to autotranspeptidation,  $K_m$  and  $V_{max}$  were calculated. The Michaelis-Menten hyperbola of L-cysteine was compared with that in the presence of 2.5 and 10 mM  $\text{Ca}^{2+}$ , and 10 mM putrescine. In addition, the known  $\gamma$ -GT inhibitors acivicin and serine-borate were tested.

#### Viability of cultured type II cells

Viability and cellular integrity were verified by Trypan Blue exclusion each time the cells were treated with the various test reagents.

#### Analysis of data

All experiments were performed on cells obtained from at least three animals with approximately  $15 \times 10^6$  cells/animal, which were divided, per animal, into control and treatment groups. All results were obtained from separate experiments and expressed as means  $\pm$  SD.  $K_m$  and  $V_{max}$  were calculated by a computerized curveplotting procedure (Fig.P software) or Hane's plot [25]. Statistical analysis was performed by the paired *t*-test using the SAS/STAT package (6th version). The level of significance was set at  $P < 0.05$ .

## RESULTS

#### Intra- and extracellular GSH and putrescine uptake

GSH levels were manipulated by four different GSH modifying compounds.

1. After 2 hr preincubation with 125  $\mu$ M BSO, an irreversible inhibitor of  $\gamma$ -glutamyl-synthetase [12], in-

tracellular GSH decreased from  $5.7 \pm 0.4$  nmol/mg at  $t = 0$  hr to  $0.9 \pm 0.5$  nmol/mg at  $t = 4$  hr ( $P = 0.008$ ), while extracellular GSH was unchanged. Putrescine uptake was not different from the control values (Fig. 2A). The apparent increase in putrescine uptake at  $t = 0$  hr could not be confirmed by further experiments, unlike the increase in GSH, which was reproducible (data not shown).

2. After 2 hr preincubation with 100  $\mu$ M DEM, which selectively depletes cytoplasmic and nuclear GSH while

conserving extracellular and mitochondrial GSH [12], intracellular GSH decreased from  $5.0 \pm 0.3$  nmol/mg at  $t = -2$  hr, to  $1.9 \pm 0.3$  nmol/mg at  $t = 0$  hr ( $P = 0.005$ ), again with no change in putrescine uptake (Fig. 2B).

3. To decrease intra- and extracellular GSH, cells were preincubated with 20  $\mu$ M NEM for 5 min [22]. Intracellular GSH decreased from  $3.8 \pm 0.1$  nmol/mg at  $t = -2$  hr to  $0.8 \pm 0.3$  nmol/mg at  $t = 1$  hr ( $P = 0.015$ ), while putrescine uptake decreased by  $39 \pm 12\%$  ( $P = 0.03$ ) (Fig. 2C).




Fig. 2. The relationship between intracellular GSH and putrescine uptake by rat type II pneumocytes: (A) 2 hr preincubation with 125  $\mu$ M BSO (horizontal bar); (B) 2 hr preincubation with 100  $\mu$ M DEM (horizontal bar); (C) 5 min preincubation with 20  $\mu$ M NEM (arrow); and (D) 1 hr coincubation with 10  $\mu$ M copper-o-phenantroline complex (CuP). Data  $\pm$  SD,  $n = 3$ , \* $p < 0.05$  vs control (paired  $t$ -test).




Fig. 2. Continued

4. Selective extracellular GSH depletion was achieved by incubation with a low concentration of the CuP complex [22]. The 10 μM CuP solution did not influence intracellular GSH during 1 hr incubation ( $3.7 \pm 0.8$  nmol/mg before vs  $3.4 \pm 0.2$  nmol/mg after incubation), but putrescine uptake decreased by  $41 \pm 7\%$  ( $P = 0.001$ ). Extracellular GSH was not detectable after incubation with CuP (control values 0.1–0.4 mM) (Fig. 2D).

#### Putrescine uptake inhibition (Table 1)

Reversible inhibition of γ-GT by 5–20 mM serine-borate [10] resulted in a decrease in putrescine uptake of  $39.5 \pm 5.7\%$  ( $n = 42$ ,  $P < 0.001$ ). Five mM L-serine, 20 mM borate, or 2.5–5 mM serine-borate gave no inhibition of putrescine uptake, but 5.0–10 mM serine-borate led to  $32.2 \pm 3.2\%$  inhibition. The specific and irrevers-

Table 1. The effect of different inhibitors of [ $^3$ H]putrescine uptake in rat type II pneumocytes

Inhibitor	n	% Decrease in uptake	
		I	I + SB
L-Serine 5 mM	6	$6.9 \pm 8.0$	NA
Borate 20 mM	6	$8.5 \pm 7.1$	NA
SB 2.5–5 mM	3	$-0.1 \pm 0.4$	NA
SB 5–10 mM	6	$32.2 \pm 3.8^*$	NA
SB 5–20 mM	42	$39.5 \pm 5.7^*$	NA
Acivicin 5 μM	3	$11.9 \pm 4.4$	ND
50 μM	3	$14.8 \pm 12.0$	ND
500 μM	3	$32.4 \pm 6.0^*$	ND
5 mM	6	$40.5 \pm 5.0^*$	$40.0 \pm 7.0$
Glutathione 10 μM	3	$20.1 \pm 17.0$	$44.0 \pm 10.1^\dagger$
20 μM	3	$49.0 \pm 9.0^*$	$44.0 \pm 10.0$
Glygly 10 μM	3	$9.4 \pm 7.2$	$36.0 \pm 5.2^\dagger$
20 μM	3	$7.5 \pm 6.7$	$36.0 \pm 4.3^\dagger$
L-Cysteine 10 μM	3	$14.0 \pm 8.0$	$34.3 \pm 11.9^\dagger$
20 μM	3	$18.6 \pm 12.5$	$37.3 \pm 13.6^\dagger$
MGBG 20 μM	6	$56.9 \pm 18.3^*$	$83.0 \pm 5.9^\dagger$
40 μM	3	$62.0 \pm 0.1^*$	ND
Cystamine 12.5 μM	3	$41.6 \pm 6.0^*$	$58.2 \pm 8.6$
25 μM	3	$55.0 \pm 11.0^*$	$66.9 \pm 13.7$
50 μM	3	$64.3 \pm 4.7^*$	$77.2 \pm 15.1^\dagger$
100 μM	3	$78.4 \pm 3.6^*$	$90.6 \pm 3.1^\dagger$
Paraquat 100 μM	3	$8.2 \pm 11.5$	$44.0 \pm 8.6^\dagger$
200 μM	3	$12.9 \pm 7.0$	$45.7 \pm 8.4^\dagger$
400 μM	3	$23.9 \pm 6.0^*$	$52.4 \pm 8.7^\dagger$
1250 μM	3	$39.7 \pm 13.1^*$	$67.3 \pm 5.0^\dagger$
2500 μM	3	$43.0 \pm 12.0^*$	$70.0 \pm 3.3^\dagger$

Inhibition of [ $^3$ H]putrescine uptake in freshly isolated rat type II pneumocytes, 24 hr after their isolation. NA not applicable, ND not determined, I = Inhibitor, SB = L-Serine-Borate (5–20 mM), I + SB = Inhibitor plus L-Serine-Borate, MGBG = methylglyoxal-bis-(guanyl-hydrazone), Glygly = Glycylglycine. I\*  $P < 0.05$  compared to the control values, I + SB; † $P < 0.05$  compared to I (paired  $t$ -test), means  $\pm$  SD.

ible  $\gamma$ -GT inhibitor acivicin [10] reduced putrescine uptake in a dose-dependent fashion, with a maximal inhibitory effect reached at 5 mM. At this concentration, putrescine uptake was decreased by  $40.5 \pm 5\%$  ( $P = 0.005$ ). The combination of both inhibitors did not augment inhibition. Cell viability was verified by Trypan Blue exclusion, but no signs of toxicity could be detected.

Ten and 20  $\mu$ M GSH inhibited putrescine uptake by 20.1 and 49.0%, respectively, without additional inhibition by serine-borate for the highest GSH concentration. L-cysteine (10 and 20  $\mu$ M), glycylglycine (10 and 20  $\mu$ M) and L-serine (5 mM) did not inhibit putrescine uptake. Preliminary experiments (data not shown) indicated that the  $K_i$  (concentration at which  $K_m$  is doubled) for MGBG was 0.57  $\mu$ M; at concentrations of 30 and 60 times the  $K_i$ , uptake was inhibited by  $56.9 \pm 18.3\%$  and  $62.0 \pm 0.1\%$ , respectively ( $P < 0.05$ ); paraquat, at the highest concentration, inhibited the uptake by  $43.0 \pm 12.0\%$  ( $P < 0.05$ ). MGBG or paraquat plus serine-borate resulted in an additive inhibitory effect, approaching the sum of the inhibitions caused by either compound alone. Preliminary experiments (data not shown) indicated that the  $K_i$  for cystamine was 9.2  $\mu$ M; at 10 times the  $K_i$ , cystamine inhibited putrescine uptake by approximately 75%, with only a minor additive inhibitory effect of serine-borate.

The apparent  $K_m$  for putrescine uptake was  $7.4 \pm 1.9$

$\mu$ M with a  $V_{max}$  of  $1030 \pm 76$  pmol/mg/hr (Fig. 3). After addition of serine-borate, the  $K_m$  remained unchanged ( $7.3 \pm 2.2$   $\mu$ M), but the  $V_{max}$  decreased by 25% ( $773 \pm 67$  pmol/mg/hr,  $p < 0.01$ ). The same results were obtained after addition of acivicin (5 mM): The  $K_m$  was  $5.9 \pm 1.4$   $\mu$ M, and the  $V_{max}$  decreased to  $757 \pm 47$  pmol/mg/hr,  $P < 0.01$ . The combination of acivicin and serine-borate resulted in a  $K_m$  of  $3.6 \pm 1.7$   $\mu$ M ( $p < 0.05$ , and a  $V_{max}$  of  $734 \pm 130$  pmol/mg/hr ( $P < 0.01$ ). However, if a Hane's plot was used to calculate the  $K_m$  and  $V_{max}$  for the inhibition with acivicin and serine-borate together, the same values as for the inhibition with serine-borate or acivicin alone were obtained.

#### The $\gamma$ -GT assay (Table 2)

The assay was validated with glycylglycine ( $K_m$  5.0 mM) and with proline, which as expected [13] was negative. Serine-borate and acivicin inhibited  $\gamma$ -GT by 90% and 85%, respectively. Table 2 shows that putrescine, spermidine, and spermine can serve as acceptor substrates for  $\gamma$ -GT, giving about equal  $K_m$  values and  $V_{max}/K_m$  ratios. Using the latter index as a measure of the relative efficiency of the substrate to serve as acceptor, it appears that the acceptor substrates glycylglycine and L-cysteine are approximately 30 and 10 times, respectively, more efficient than putrescine. The diamine cystamine also acts as an acceptor substrate for  $\gamma$ -GT, with




Fig. 3. The non-competitive inhibition of putrescine uptake by acivicin and serine-borate in rat type II cells. Abbreviations: SB = serine-borate; A = acivicin. Panel D: Hane's plot:  $K_m$  remains the same.  $V_{max}$  decreases by 25% during inhibition with SB, A or SB + A. Means  $\pm$  SD,  $n = 3$  (paired  $t$ -test). Units of y-axis were taken as ratio of putrescine concentration and values of y-axis of panels A, B, or C.

Table 2. Kinetic properties of  $\gamma$ -GT for different potential acceptors

Acceptor	$K_m$ (mM)	$V_{max}$ (U/L)	$V_{max}/K_m$ min <sup>-1</sup>
Glygly	5.0 $\pm$ 1.9	2167 $\pm$ 384	433
L-Cysteine	4.5 $\pm$ 2.5	589 $\pm$ 230	131
Cystamine	94.6 $\pm$ 10.1	370 $\pm$ 14	4
Putrescine	4.2 $\pm$ 1.0	55 $\pm$ 4	13
Spermidine	1.1 $\pm$ 0.4	15 $\pm$ 1	14
Spermine	4.2 $\pm$ 0.7	18 $\pm$ 11	4
Paraquat	no acceptor		
MGBG	no acceptor		
Proline	no acceptor		

Glygly = glycylglycine, U = units (i.e. micromoles nitroaniline release/min). Experimental conditions: 0.2 mL L- $\gamma$ -glutamyl-p-nitroanilide 1 mM, 0.59 mL 0.1 M Tris-HCl buffer pH 8.0, 0.2 mL acceptor, and 10  $\mu$ L  $\gamma$ -GT (60 U/mL) at 37°C. The absorbance was measured at 410 nm for 2 min (means of three observations  $\pm$  SD).

high  $K_m$  and  $V_{max}$  values, but similar enzyme efficiency compared to the oligoamines. Although paraquat and MGBG [2, 3, 5, 6] are known inhibitors of (one of) the putrescine uptake pathway(s), they proved not to be acceptor substrates for  $\gamma$ -GT.

As putrescine has been described as an "organic calcium" because of its two positive charges at physiological pH, and because monovalent cations and divalent metal ions are reported to activate  $\gamma$ -GT [10], we investigated the effect of 2.5 and 10 mM  $\text{Ca}^{2+}$ , and 10 mM putrescine on the  $K_m$  and  $V_{max}$  of L-cysteine (Fig. 4). The apparent kinetic properties for L-cysteine, L-cysteine plus 2.5 mM  $\text{Ca}^{2+}$ , L-cysteine plus 10 mM  $\text{Ca}^{2+}$ , or L-cysteine plus 10 mM putrescine were unchanged with values of 4.5, 3.4, 4.3, and 4.3 mM, respectively, for  $K_m$ , and 589, 527, 582, and 592 U/L for  $V_{max}$ .

### DISCUSSION

The oligoamines putrescine, spermidine, and spermine are required for cell growth, differentiation, and proliferation. It has been established that tumors or rap-




Fig. 4. Effect of 2.5 or 10 mM  $\text{Ca}^{2+}$ , or 10 mM putrescine on the activity of  $\gamma$ -GT; 0.2 mL L- $\gamma$ -glutamyl-p-nitroanilide 1 mM, 0.59 mL 0.1 M Tris-HCl buffer pH 8.0, 0.2 mL L-cysteine at different concentrations, and 10  $\mu$ L  $\gamma$ -GT (60 U/mL) were mixed, and the change in absorbance measured at 410 nm for 2 min at 37°C. There was no difference between the  $K_m$  and  $V_{max}$  values of the different curves (means  $\pm$  SD).

idly proliferating cells require oligoamines in increasing amounts [1]. Especially in these situations, oligoamine uptake can complement or substitute for *de novo* biosynthesis of oligoamines. This uptake has been studied in a number of cells, and was observed to be a saturable, carrier-mediated, and energy-dependent system [2–9]. Many studies of this system have focused on its use by other compounds, as evidenced by the competitive inhibition of polyamine uptake by their analogues or vice versa, but the transporter has not yet been identified or purified [6]. Genes responsible for the phenotypic expression of oligoamine transport have been cloned from both *E. coli* and human DNA [26, 27], and a number of different clones have been identified with different properties, which might be consistent with the multiplicity of the polyamine transport system. However, the amino acid sequences of the transport protein(s) are as yet unknown. Mainly on the grounds of kinetic considerations, some authors believe that only one uptake system is involved [3], whereas others have suggested at least two uptake systems [2, 6, 8], some of them  $\text{Na}^+$  dependent and sensitive to SH-group reagents [28].

It is assumed that GSH and closely related  $\gamma$ -glutamyl compounds are the physiological substrates of the enzyme  $\gamma$ -GT [10]. Because  $\gamma$ -GT and its substrate GSH are located on opposite sides of a membrane, intracellular GSH may be first exported to the extracellular space, where it is bound to  $\gamma$ -GT [29] (Fig. 1).

### Summary of findings and hypothesis

Our hypothesis was that one of the routes by which the oligoamine putrescine might enter the type II pneumocyte is via  $\gamma$ -GT. Our findings can be summarized as follows: exposure of type II pneumocytes to BSO and DEM, both of which decrease only intracellular GSH [12], did not change putrescine uptake, but exposure to NEM, which affects intra- and extracellular GSH [12, 22], decreased putrescine uptake. Selective extracellular GSH depletion with CuP, while conserving intracellular GSH [22], decreased putrescine uptake as well. Specific inhibition of  $\gamma$ -GT by serine-borate gave the same degree of putrescine uptake inhibition as that caused by acivicin and CuP. L-serine, cysteine, and glycylglycine did not inhibit putrescine uptake, but GSH did, although without any additive inhibitory effect of serine-borate. MGBG and paraquat decreased putrescine uptake, but even though "infinite" concentrations (compared to the  $K_i$  values) were used, putrescine uptake could be inhibited only by 62 and 43%, respectively. If serine-borate was added, the inhibition approached the sum of the inhibition by MGBG or paraquat and serine-borate. Cystamine inhibited putrescine uptake by approximately 75%, with only 15% additional inhibitory effect of serine-borate being obtained at the highest concentrations of cystamine. The characteristics of the putrescine uptake system in the presence of acivicin and serine-borate show that  $V_{max}$  decreased by 25% with no change in  $K_m$ . In test-tube experiments with pure  $\gamma$ -GT, the oligoamines putrescine, spermidine and spermine, and cystamine proved to be acceptor substrates for  $\gamma$ -GT, all having similar efficiencies ( $V_{max}/K_m$ ), but MGBG and paraquat were not accepted as substrates.

### Technical aspects

L-serine in the presence of borate is known to inhibit  $\gamma$ -GT in a reversible way [10]. Neither compound alone

inhibits the enzyme, which means that effects not dependent on the simultaneous presence of both compounds may not be attributed to inhibition of  $\gamma$ -GT [10]. In our experiments, L-serine or borate alone did not inhibit putrescine uptake, making the possibility of atypical effects (i.e. changes in charge) less likely. Moreover, in the  $\gamma$ -GT assay the kinetic parameters did not change in the presence of calcium, or the dicationic putrescine (Fig. 4), and it was possible to inhibit putrescine uptake as much, and with the same kinetic properties, by acivicin, a well-established irreversible  $\gamma$ -GT inhibitor, by virtue of its covalent binding to the glutamyl portion of the substrate binding site [10]. The aim of the  $\gamma$ -GT study was to demonstrate that oligoamines can serve as acceptor substrate for the enzyme, and to express the efficiency of the enzyme to handle oligoamines compared to other known acceptor substrates. To validate our experimental setup, we determined the  $K_m$  for glycylglycine, with the value found (5.0 mM) being in the same range as those found by others (2.96 and 9.5 mM) [10, 24].

### Interpretation

Our results indicate that extracellular -SH groups are required for putrescine uptake. These -SH groups might belong to membrane proteins, to the transporter protein, or to the donor substrate for  $\gamma$ -GT (i.e. GSH). If extracellular GSH was depleted by CuP, putrescine uptake was inhibited as much as by the specific  $\gamma$ -GT inhibitors serine-borate and acivicin. These results support our hypothesis that putrescine can be taken up via the  $\gamma$ -glutamyl cycle. Presuming that the  $\gamma$ -GT route is completely inhibited by serine-borate or acivicin, the fact that similar  $K_m$  values were found pre- and post-inhibition might be explained by equal affinities of putrescine for both systems. This would be consistent with our previous kinetic studies on putrescine uptake in type II pneumocytes [3].

The observations that putrescine uptake inhibition by serine-borate was additive to MGBG and paraquat (Table 2), and that the oligoamines proved to be acceptor substrates for  $\gamma$ -GT in the  $\gamma$ -GT assay, in contrast to MGBG and paraquat, indicate that there could be at least two uptake pathways. Oreffo *et al.* [30] came to the same conclusion: "... we cannot exclude the possibility that type II cells have two separate uptake systems, one involving competitive inhibition of the diamine (paraquat) by the polyamine (putrescine), and the other solely for polyamine accumulation." Data from our experiments with cystamine suggest that cystamine has affinity for both pathways, an observation shared by others [31]. There is likely a higher inhibitory affinity for the  $\gamma$ -GT pathway, because serine-borate had only a 15% additive inhibitory effect.

Specificity studies [10] have provided evidence for three separate subsites in the active centre of  $\gamma$ -GT: the  $\gamma$ -glutamyl donor site, with broad optical and steric specificity, and the acceptor site, consisting of subsites 2 and 3 for the cysteinyl and glycyl moieties of GSH. Acceptor amino acids will only produce an inhibition of  $\gamma$ -GT if they bind to the acceptor binding site 2 or 3, if they overlap with a portion of the  $\gamma$ -glutamyl donor site, or if they bind to the sites that normally bind the amino and carboxyl groups of the  $\gamma$ -glutamyl donor [16]. Dipeptides (glycylglycine) seem to bind only to the acceptor subsite (subsite 2 or 3) [32, 33]. The fact that L-serine,

cysteine, and glycylglycine did not inhibit putrescine uptake might indicate that oligoamines do not bind to the acceptor binding site, but probably in part to the  $\gamma$ -glutamyl donor site. The inhibition by GSH might be explained by competitive inhibition with the oligoamines at this  $\gamma$ -glutamyl donor site. A free terminal amino group is probably also a prerequisite, since MGBG and paraquat do not appear to be acceptor substrates for  $\gamma$ -GT.

### CONCLUSION

Our data indicate that 30–40% of putrescine uptake in rat type II pneumocytes may occur via  $\gamma$ -GT, and that at least two systems are thus involved in putrescine uptake. Moreover, there is evidence for a link between extracellular GSH and putrescine uptake. These results might be of clinical relevance: As putrescine is involved in growth and differentiation of cells, changes in extracellular GSH or  $\gamma$ -GT by, for example, oxidative stress might have repercussions on normal cell growth and differentiation.

**Acknowledgement**—This research project was partly sponsored by the "BIOMED" research programme (BMH1-CT92-1229), funded by the Commission of the European Communities.

### REFERENCES

1. Heby O, Role of polyamines in the control of cell proliferation and differentiation. *Differentiation* **19**: 1–20, 1981.
2. Beers TO, Cambogia R, Rannels DE and Pegg A, Multiple pathways for uptake of paraquat, methylglyoxal bis(guanyl-hydrazone), and polyamines. *Am J Physiol* **252**: C663–C669, 1987.
3. Hoet PHM, Lewis CPL, Demedts M and Nemery B, Putrescine and paraquat uptake in human lung slices and isolated type II pneumocytes. *Biochem Pharmacol* **48**: 517–524, 1994.
4. Hoet PHM, Dinsdale D, Lewis CPL, Verbeken EK, Lauweryns JM and Nemery B, Kinetics and cellular localisation of putrescine uptake in human lung tissue. *Thorax* **48**: 1235–1241, 1993.
5. O'Sullivan MC, Golding BT, Smith LL and Wyatt I, Molecular features necessary for the uptake of diamines and related compounds by the polyamine receptor of rat lung slices. *Biochem Pharmacol* **41**: 1839–1848, 1991.
6. Chen N, Bowles MR and Pond SM, Competition between paraquat and putrescine for uptake by suspensions of rat alveolar type II cells. *Biochem Pharmacol* **44**: 1029–1036, 1992.
7. Khan NA, Quemener V and Moulinoux J-PH, Polyamine membrane transport regulation. *Cell Biol Int Rep* **15**: 9–24, 1991.
8. Seiler N and Dezeure F, Polyamine transport in mammalian cells. *Int J Biochem* **20**: 211–218, 1990.
9. Khan NA, Quemener V, Seiler N and Moulinoux J-PH, Characterization of spermine transport and its inhibition with polyamine analogues in cultured mammalian cells. *Exp Cell Biol* **58**: 172–178, 1990.
10. Meister A, Tate SS and Griffith OW,  $\gamma$ -glutamyl transpeptidase. *Methods Enzymol* **77**: 237–253, 1981.
11. Griffith OW and Meister A, Translocation of intracellular glutathione to membrane-bound  $\gamma$ -glutamyl transpeptidase as a discrete step in the  $\gamma$ -glutamyl cycle: Glutathionuria after inhibition of transpeptidase. *Proc Natl Acad Sci USA* **76**: 268–272, 1979.
12. Meister A, Methods for the selective modification of glutathione metabolism and study of glutathione transport. *Methods Enzymol* **113**: 571–586, 1985.
13. Griffith OW, Bridges RJ and Meister A, Transport of  $\gamma$ -glu-



- tamyl amino acids: Role of glutathione and  $\gamma$ -glutamyl-transpeptidase. *Proc Natl Acad Sci USA* **76**: 6319–6322, 1979.
14. Bard S, Noel P, Chauvin F and Quash G,  $\gamma$ -Glutamyl-transpeptidase activity in human breast lesions: An unfavourable prognostic sign. *Brit J Cancer* **53**: 637–642, 1986.
  15. Tateishi N, Higoshi T, Nomura T, Naruse A, Nakashima K, Shiozaki H and Sakamoto Y, Higher transpeptidation activity and broad acceptor specificity of  $\gamma$ -glutamyltranspeptidase of tumours. *Gann* **67**: 215–222, 1976.
  16. Schrode J and Folk JE, Transglutaminase-catalyzed cross-linking through diamines and polyamines. *J Biol Chem* **253**: 4837–4840, 1978.
  17. Haddock Russell D and Womble JR, Transglutaminase may mediate certain physiological effects of endogenous amines and of amine-containing therapeutic agents. *Life Sciences* **30**: 1499–1508, 1982.
  18. Allison RD,  $\gamma$ -Glutamyl transpeptidase: kinetics and mechanism. *Methods Enzymol* **13**: 419–437, 1985.
  19. Richards RJ, Davies N, Atkins J and Oreffo VIC, Isolation, biochemical characterization and culture of lung epithelial type II cells of the rat. *Lung* **165**: 143–158, 1987.
  20. Anderson ME, Determinations of glutathione and glutathione disulfide in biological samples. *Methods Enzymol* **113**: 548–554, 1985.
  21. Bradford MM, Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* **72**: 248–254, 1976.
  22. Duncan DD and Laurence DA, Four different sulfhydryl modifying compound cause different structural damage but similar functional damage in murine lymphocytes. *Chem Biol Interact* **68**: 137–152, 1988.
  23. Kobashi K, Catalytic oxidation of sulfhydryl groups by o-phenanthroline copper complex. *Biochim Biophys Acta* **158**: 239–245, 1968.
  24. Huseby NE and Strömme JH, Practical points regarding routine determination of  $\gamma$ -glutamyl transferase ( $\gamma$ -GT) in serum with a kinetic method at 37°C. *Scand J Clin Lab Invest* **34**: 357–363, 1974.
  25. Engel PC, *Outline Studies in Biology: Enzyme Kinetics, Steady-State Approach*. Chapman and Hall, London, 1981.
  26. Byers TL, Wechter R, Nuttall ME and Pegg A, Expression of a human gene for PA transport in Chinese-hamster ovary cells. *Biochem J* **263**: 745–752, 1989.
  27. Kashiwagi K, Hosokawa N, Takemitsu F, Kobayashi H, Sasakawa C, Yoshikawa M and Igarashi K, Isolation of polyamine transport-deficient mutants of *Escherichia coli* and cloning of the genes for polyamine transport proteins. *J Biol Chem* **265**: 20893–20897, 1990.
  28. De Smedt H, Van Den Bosch L, Geuns J, Borghgraef R, Polyamine transport systems in the LLC-PK<sub>1</sub> renal established cell line. *Biochim Biophys Acta* **1012**: 171–177, 1989.
  29. Meister A, and Anderson ME, Glutathione. *Annu Rev Biochem* **52**: 713–754, 1983.
  30. Oreffo VIC, John RA and Richards RJ, Diamine uptake by rat lung type II cells *in vitro*. *Biochem Pharmacol* **41**: 1209–1215, 1991.
  31. Lewis CPL, Haschek WM, Wyatt I, Cohen GM and Smith LL, The accumulation of cystamine and its metabolism to taurine in rat lung slices. *Biochem Pharmacol* **38**: 481–488, 1989.
  32. Thompson GA and Meister A, Interrelationships between the binding sites for amino acids, dipeptides, and  $\gamma$ -glutamyl donors in  $\gamma$ -glutamyltranspeptidase. *J Biol Chem* **252**: 6792–6798, 1977.
  33. Tate SS and Meister A, Interaction of  $\gamma$ -glutamyl transpeptidase with amino acids, dipeptides, and derivatives and analogs of glutathione. *J Biol Chem* **249**: 7593–7602, 1974.